Cyriac Roeding is a German-American entrepreneur and investor based in Silicon Valley. He currently serves as the co-founder and CEO of Earli, an early cancer detection and treatment firm located in Redwood City, California. Earli's approach involves using a genetic construct that activates only in cancer cells to trigger the immune system. This concept, originating at Stanford University, has been advanced through AI and extensive bioengineering.